 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Basis of Gliomas slide presentation is not an independent educational.

Slides:

Advertisements

Similar presentations

Kwee Yong, UCL Cancer Institute

Advertisements

Cancer: a genetic disease of inherited and somatic mutations n Gene mutations and/or genetic instability are involved in many cancers. n Viruses and environmental.

 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Basis of Colorectal Cancer slide presentation is not an independent.

 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Basis of Cancer (MBoC): Fundamental and Evolving Concepts slide presentation.

Cell Signaling, Wound Repair, and ATP Receptors Kevin Quirke and Alex Knobloch.

 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Biomarkers in Cancer (MBiC) slide presentation is not an independent.

Dr MOHAMED FAKHRY MOLECULAR BASIS OF CANCER.

Gene 210 Cancer Genomics May 5, Key events in investigating the cancer genome M R Stratton Science 2011;331:

By: Katie Adolphsen, Robin Aldrich, Brandon Hu, Nate Havko.

BRF Begin with BRAF Searching for a target in metastatic melanoma?

 2014 Genentech USA, Inc. All rights reserved. 1 Disclosure/Disclaimer The Molecular Basis of Cancer Educational Series is not intended to promote any.

 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Basis of Lung Cancer slide presentation is not an independent educational.

 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Basis of Breast Cancer slide presentation is not an independent educational.

The Promise of Immunotherapy for Cancer Treatment

 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Basis of Hematological Malignancies slide presentation is not an independent.

Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master’s Programmes at the University.

Benign tumor: abnormal proliferation of cells that remain Contained and don’t spread to other tissues (ex. Skin wart) Malignant tumor: cells are capable.

Cancer --an Overview  Cell Division  Hormones and Cancer  Malignant Transformation  Angiogenesis and Metastasis  Growth.

Cancer Tumor Cells and the Onset of Cancer

Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.

Genetics of Cancer Genetic Mutations that Lead to Uncontrolled Cell Growth.

G 1 and S Phases of the Cell Cycle SIGMA-ALDRICH.

Benign Versus Malignant Tumors

Basic Immunology of the Mouse (and Human) Nicholas P. Restifo, MD October 19, 2015.

Lecture 12: Cancer: a cellular perspective Dr. Mamoun Ahram Faculty of Medicine Second year, Second semester, Principles of Genetics and Molecular.

Module 4: How do unrealistic expectations confound the results of our analyses Case Studies in Bioinformatics Giovanni Ciriello

Dr. Hiba Wazeer Al Zou’bi

Neoplasia 4 Dr. Hiba Wazeer Al Zou’bi. 4- Nuclear Transcription Factors: DNA transcription regulated by genes e.g. MYC, MYB, JUN, FOS, REL oncogenes 

Cell Growth & Division Control of Cell Cycle | Disruptions to Cell Cycle.

Cancer immunotherapy: an update

Samsung Genome Institute Samsung Medical Center

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Combinatorial interactions of cyclins and cyclin-dependent kinases (cdks) during the cell cycle. Progression from G0 through the restriction point in G1.

Targeting signal transduction

Biologic therapy of inflammatory bowel disease

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Regulation of the Cell Cycle & Cancer

Sixto M. Leal, Margaret L. Gulley The Journal of Molecular Diagnostics

The Immune System. The Immune System Adaptive Immune Response.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Signalling pathways and physiological domains that are

Treatment of Glioma in the 21st Century: An Exciting Decade of Postsurgical Treatment Advances in the Molecular Era Joon H. Uhm, MD, Alyx B. Porter,

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Possible combination therapies CDK4/6 inhibitors

The Cell Cycle and Understanding Cancer

Dan Gordon Gastroenterology Volume 114, Issue 4, (April 1998)

Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma Darshil J. Shah, MD, MPH, Roxana S. Dronca,

Figure 1 A schematic representation of the HER2 signalling pathway

Volume 150, Issue 3, Pages (September 2018)

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Endocrinol. doi: /nrendo

Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non–Small Cell Lung Cancer Alexa B. Schrock, PhD, Allison.

Figure 1 The role of CTLA4 and PD1 in T cell activation

Figure 2 Site of action of checkpoint inhibitors and agonists being

Nat. Rev. Urol. doi: /nrurol

Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening–Detected Lung Cancers Carla Verri, MSc, Cristina Borzi, MSc, Todd Holscher,

Figure 2 Frequency and overlap of alterations

Nat. Rev. Endocrinol. doi: /nrendo

M.B.Ch.B, MSC, PhD, DCH (UK), MRCPCH

Figure 1 Mechanisms of action of immunotherapy modalities

Schematic representation of signaling by high-risk human papillomavirus HPV E7. Schematic representation of signaling by high-risk human papillomavirus.

Genes frequently mutated in colorectal cancer and their relationships with miRNAs. Genes frequently mutated in colorectal cancer and their relationships.

Simon Ekman, MD, PhD, Murry W. Wynes, PhD, Fred R. Hirsch, MD, PhD

Canonical gliomagenesis mediators EGFR, P53, and retinoblastoma protein (RB1) are important for cancer signaling. Canonical gliomagenesis mediators EGFR,

BC Basics 2017.

Figure 4 Molecular signalling and immunological

Schematic representation of signaling by HTLV-1 Tax.

Presentation transcript:

 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Basis of Gliomas slide presentation is not an independent educational program, and no CME credits will be provided. This program is not intended to promote any cancer agent or class approved by the FDA/EMA or currently under clinical development. The contents of this slide presentation are owned solely by Genentech; any unauthorized uses are prohibited. This program is presented on behalf of Genentech and the information presented is consistent with FDA guidelines. The following slides are selected samples from a complete presentation. They are for educational purposes only. BIO

 2013 Genentech USA, Inc. All rights reserved. 2 Driver mutations can be classified into cell signaling pathways CDKN2A=cyclin-dependent kinase inhibitor 2A; MDM2=MDM2 oncogene; MDM4=Mdm4 p53 binding protein homolog; TP53=tumor protein p53; EGFR=epidermal growth factor receptor; ERBB2=v-erb-b2 erythroblastic leukemia viral oncogene homolog 2; PDGFRα=platelet derived growth factor alpha; Ras=rat sarcoma; NF1=neurofibromin 1; PI3K=phosphatidylinositol 3-kinase; PTEN=phosphatase and tensin homolog; FOXO=forkhead box O1; CDKN2B=cyclin-dependent kinase inhibitor 2B; CDKN2C=cyclin-dependent kinase inhibitor 2C; CDK4=cyclin-dependent kinase 4 CCND2=cyclin D2; CDK6=cyclin-dependent kinase 6; Rb1=retinoblastoma 1. Vogelstein B, et al. Science. 2013;339: The Cancer Genome Atlas Research Network. Nature. 2008;455: PI3K Akt PTEN FOXO NF1 Ras Proliferation Survival Translation EGFR ERBB2MET PDGFR  Activated oncogenes CDK2NA MDM2 MDM4 TP53 SenescenceApoptosis CDKN2ACDKN2BCDKN2C CDK4CDK6CCND2 Rb1 G1/S progression p53 signaling altered in 87% RTK/Ras/PI3K signaling altered in 88% Rb signaling altered in 78% The commonly implicated pathways leading to growth advantage in glioblastoma multiforme (GBM). Reference: The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455: Notes

 2013 Genentech USA, Inc. All rights reserved. Tumor-specific immunotherapy via HSP-conjugated vaccine Glioma antigens bound to HSPs elicit specific immune responses Following immunization, HSPPC-96–antigen complexes are internalized by APCs via CD91 receptor APCs then present to CD8+ T cells on MHC class I CD8+ T cell MHC I TCR HSPPC-96–antigen Resected tumor APC CD91 HSP=heat shock protein; APCs=antigen-presenting cells; MHC=major histocompatibility complex; PFS=progression-free survival; TCR=T-cell receptor. Crane CA, et al. Clin Cancer Res. 2013;19: Abbas AK, Lichtman AH, eds. Basic Immunology: Functions and Disorders of the Immune System. 2nd ed. Philadelphia, PA: Saunders; 2004: Tanaka S, et al. Nat Rev Clin Oncol. 2013;10:

 2013 Genentech USA, Inc. All rights reserved. Therapies that target the epigenome Histone deacetylase (HDAC) reduces the expression of genes associated with cell-cycle regulation HAT  Proliferative signaling  Proliferation SMI  Proliferation Ac HDAC Ac=acetylation; SMI=small-molecule inhibitor; HAT=histone acetylases. Azad N, et al. Nat Rev Clin Oncol. 2013;10:

 2013 Genentech USA, Inc. All rights reserved. alkylating agent Unmethylated MGMT promoter MGMT DNA repair Cell survival Biomarkers in malignant glioma: MGMT methylation MGMT=O 6 -methylguanine-DNAmethyltransferase. 5

 2013 Genentech USA, Inc. All rights reserved. Methylated MGMT promoter Cell death Alkylating agent Biomarkers in malignant glioma: MGMT methylation MGMT=O 6 -methylguanine-DNAmethyltransferase. 6